Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mesoblast Limited ( (AU:MSB) ) just unveiled an update.
Mesoblast released financial results and an operational update for the period ended December 31, 2025, outlining its performance and recent developments in the business. The company highlighted expectations around sales, regulatory progress, manufacturing scalability, intellectual property strength and capital needs, while emphasizing that these projections are subject to significant clinical, regulatory and commercial risks.
The update underscores Mesoblast’s continued focus on advancing its adult stem cell technologies and expanding its partnerships to grow its commercial footprint. Investors and other stakeholders are reminded that outcomes may differ materially from management’s expectations due to uncertainties in clinical trials, regulatory approvals, funding requirements and market conditions.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on allogeneic cellular medicines for inflammatory diseases. Listed on the ASX under MSB and on Nasdaq under MESO, it develops adult stem cell-based therapies aimed at treating serious inflammatory conditions, positioning itself within the global regenerative medicine and advanced therapeutics market.
Average Trading Volume: 3,790,800
Technical Sentiment Signal: Buy
Current Market Cap: A$2.97B
Learn more about MSB stock on TipRanks’ Stock Analysis page.